A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
NCT07572240, Not applicable, Completed, Rousselot BVBA
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals | ClinicalTrials.gov |
| NCT number | NCT07572240 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 72 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Rousselot BVBA | ClinicalTrials.gov |
| Conditions | Healthy, Stress | ClinicalTrials.gov |
| Interventions | AP-Brain Collagen Peptide | ClinicalTrials.gov |
| First posted | 2026-05-07 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline and Different Doses on Selective Attention and Focus by Stroop Color-Word Test at Day 56 | Baseline and Day 56 | The Stroop Color Word Test is a validated neuropsychological assessment used to measure selective attention, cognitive flexibility, processing speed, and executive control. The test requires participants to identify the ink color of printed words that may represent incongruent color names, thereby assessing the ability to inhibit automatic responses and manage cognitive interference. The change in selective attention and focus will be measured by change in mean reaction time (ms) and stroop latency by Stroop Color-Word test. | ClinicalTrials.gov |
| Secondary | Change from Baseline and Different Doses on Selective Attention and Focus by Stroop Color-Word Test at Day 28 | Baseline and Day 28 | The Stroop Color Word Test is a validated neuropsychological assessment used to measure selective attention, cognitive flexibility, processing speed, and executive control. The test requires participants to identify the ink color of printed words that may represent incongruent color names, thereby assessing the ability to inhibit automatic responses and manage cognitive interference The change in selective attention and focus will be measured by change in mean reaction time (ms) and stroop latency by Stroop Color-Word test. | ClinicalTrials.gov |
| Secondary | Change from Baseline and Different Doses on Sustained Attention by Continuous Performance Test (CPT) at Day 28 and Day 56 | Baseline, Day 28, and Day 56 | The CPT measures sustained attention of participants to predefined target sequence in two phases (Phase X where participant has to respond to target "X" and phase AX where participant has to respond to target "AX" (e.g., "A" followed by "X") and withhold responses to non-target sequences. The change in sustained attention is measured through change in mean response time (ms), omission rates (xtestomissionerrorrate during phase X and axtestomissionerrorrate during phase AX), commission rates (xtestcomissionerrorrate during phase X and axtestcomissionerrorrate during phase AX). | ClinicalTrials.gov |
| Secondary | Change from Baseline and Different Doses on Memory by Change in Maximal Digit Span by Digit Span Test at Day 28 and Day 56 | Baseline, Day 28, and Day 56 | The Digit Span Test is a standardized neuropsychological measure used to assess working memory capacity and attentional control. It includes two components: Digit Span Forward, in which individuals repeat a sequence of numbers in the same order as presented, and Digit Span Backward, in which they recall the numbers in reverse order. The change in memory will be measured by change of maximum digit span the longest correctly recalled sequence length (fML: maximal forward span; bML: maximal backward span) and the mean span, defined as the list length at which 50% of sequences are correctly recalled (fMS: expected forward span correct 50% of the time across 14 trials; bMS: expected backward span correct 50% of the time across 14 trials). | ClinicalTrials.gov |
| Secondary | Change from Baseline and Different Doses on Stress by Perceived Stress Scale (PSS) at Day 28 and Day 56 | Baseline, Day 28, and Day 56 | The PSS is a 10-item questionnaire with a recall period of 1 month, designed to examine participants' self-reported levels of stress during the past month by examining their thoughts and feelings. Each question is rated on a scale of 0 (never) to 4 (very often). The PSS provides a total score out of 40, where a higher score indicates higher levels of self-perceived stress. | ClinicalTrials.gov |
| Other | Brain Function Assessed through Latency and Amplitude by P300 Electroencephalogram (EEG) at Baseline and Day 56 | Baseline and Day 56 | Event-related potentials will be elicited using a standard P300 paradigm. P3b latency and P3b amplitude will be quantified. P3b latency will be defined as time internal (milliseconds) from stimulus onset to the maximum positive peak within expected P300 time window. P3b amplitude will be measured as the voltage difference (microvolts) between baseline and the peak of the P3b component. | ClinicalTrials.gov |
| Other | Change from Baseline and Different Doses on Synaptic Plasticity by Brain Derived Neutrophic Factor (BDNF) at Day 56 | Baseline and 1 hour post-dose Day 56 | Change of BDNF levels to determine acute neurotrophic response and synaptic plasticity via blood sample collection. | ClinicalTrials.gov |
| Other | Change in Baseline and Different Doses in Stress by Cortisol/Dehydroepiandrosterone sulfate (DHEAS) ratio at Day 56 | Baseline and 1 hour post-dose Day 56 | Change in ratio of cortisol/DHEAS levels to determine stress via blood sample collection. | ClinicalTrials.gov |
| Other | Change in Baseline and Different Doses in Inflammation by Tumor Necrosis Factor Alpha (TNF-α) Levels at Day 56 | Baseline and 1 hour post-dose Day 56 | Change of TNF-α levels to determine inflammation via blood sample collection. | ClinicalTrials.gov |
| Other | Change from Baseline and Different Doses on Oxidative Stress by Malondialdehyde (MDA) Levels at Day 56 | Baseline and 1 hour post-dose Day 56 | Change of MDA levels to determine systemic oxidative stress via blood sample collection. | ClinicalTrials.gov |
| Other | Change in Baseline and Different Doses on Cognition Status by Addenbrooke's Cognitive Examination III (ACE III) at Day 56 | Baseline and Day 56 | Change in cognition status will be assessed using the ACE-III. The ACE-III provides a total score out of 100, where a higher score indicates better cognitive function. The assessment covers five cognitive domains of orientation/attention, memory, fluency, language, and visuospatial function. | ClinicalTrials.gov |
| Other | Change from Baseline and Different Doses on Cyclic Glycine-Proline (cGP) Levels at Day 56 | Baseline and 1 hour post-dose Day 56 | Change of cGP levels via blood sample collection. | ClinicalTrials.gov |
| Other | Change from Baseline and Different Doses on Insulin-Like Growth Factor-1 (IGF-1) Levels at Day 56 | Baseline and 1 hour post-dose Day 56 | Change of IGF-1 levels via blood sample collection. | ClinicalTrials.gov |
| Other | Change from Baseline and Different Doses on Blood Pressure at Day 28 and Day 56 | Baseline, Day 28, and Day 56 | Change in vitals assessed through blood pressure with units of mmHg. | ClinicalTrials.gov |
| Other | Safety Assessed by Liver Function Test from Baseline and Day 56 | Baseline and 1 hour post-dose Day 56 | Safety of test product assessed by liver function test obtained via blood sample. The liver function test will include evaluation of aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, total bilirubin, and total proteins. | ClinicalTrials.gov |
| Other | Change from Baseline and Different Doses on Pulse Rate at Day 28 and Day 56 | Baseline, Day 28, and Day 56 | Change in vitals assessed through pulse rate to provide beats per minute (bpm). | ClinicalTrials.gov |
| Other | Safety Assessed by Complete Blood Count Monitoring from Baseline and Day 56 | Baseline and 1 hour post-dose Day 56 | Safety of test product assessed by complete blood count obtained via blood sample. The complete blood count will include evaluation of hematocrit, hemoglobin, platelet, red blood cell count, white blood cell count, neutrophil, lymphocyte, monocyte, eosinophil, and basophil. | ClinicalTrials.gov |
| Other | Safety Assessed by Fasting Blood Glucose from Baseline and Day 56 | Baseline and 1 hour post-dose Day 56 | Safety of test product assessed by fasting blood glucose levels obtained via blood sample. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Continuous Performance Test | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)